Skip to main content
. 2021 May 3;118(19):e2100939118. doi: 10.1073/pnas.2100939118

Fig. 4.

Fig. 4.

Decitabine inhibits proliferation of Teff cells and generates iTreg cells. (A) CFSE-stained spleen cells were treated with anti-CD3 antibody, IL-2, and decitabine. Proliferation of FoxP3−CD4+ T cells was determined by FACS. (B) CFSE-stained spleen cells from arthritic mice were stimulated with anti-CD3 antibody, IL-2, and decitabine ± ENT1 inhibitor (NBMPR; 100 μM). Proliferation of CFSE-labeled FoxP3−CD4+ T cells was determined by FACS. (C) Naive CD4+ T cells were treated with anti-CD3 antibody, IL-2, and decitabine. DNA fragmentation and apoptosis were determined by comet assay and annexin V/PI apoptosis kit. (D) Naive CD4+ T cells were treated with anti-CD3 antibody, IL-2, and decitabine (0.5 μM). ENT1 expression of naive CD4+ T cells was determined by FACS and apoptosis was determined by annexin V/PI apoptosis kit. (E) Naive CD4+ T cells treated with decitabine and anti-CD3 antibody/IL-2. Treg and non-Treg cells were quantified by FACS. *P < 0.05, **P < 0.01, ***P < 0.001.